FDA grants ANDA approval to olopatadine hydrochloride for ocular allergy relief
Products

FDA grants ANDA approval to olopatadine hydrochloride for ocular allergy relief

Generic of Alcon’s Pataday Once Daily Relief is intended for use as an antihistamine to treat itchy eyes.
FDA grants ANDA approval for brimonidine tartrate and timolol maleate 0.2%|0.5%
Products

FDA grants ANDA approval for brimonidine tartrate and timolol maleate 0.2%|0.5%

Generic of AbbVie’s Combigan is formulated to lower IOP in glaucoma and ocular hypertension (OHT) patients.
FDA approves ANDA for generic ketorolac tromethamine ophthalmic solution 0.5%
Products

FDA approves ANDA for generic ketorolac tromethamine ophthalmic solution 0.5%

Generic of Allergan’s ACULAR is indicated to treat post-op pain and inflammation plus allergic conjunctivitis.
FDA approves ANDA for Lupin's allergic conjunctivitis eye drop
Products

FDA approves ANDA for Lupin's allergic conjunctivitis eye drop

Generic equivalent to Bausch + Lomb’s Alrex offers a lower-cost alternative for patients.
FDA approves ANDA for Lupin's bromfenac ophthalmic solution 0.09%
Pipeline

FDA approves ANDA for Lupin's bromfenac ophthalmic solution 0.09%

Topical drug is the generic equivalent of Bausch + Lomb’s Bromday; intended to treat pain and inflammation following cataract surgery.
Innovent's Sycume meets phase 3 endpoint for inactive TED
Pipeline

Innovent's Sycume meets phase 3 endpoint for inactive TED

RESTORE-3 trial demonstrates efficacy in reducing proptosis and a favorable safety profile for patients with inactive TED.
Oku Digital Health launches from Topcon with AI retinal screening network, oculomics
Business

Oku Digital Health launches from Topcon with AI retinal screening network, oculomics

Digital health company debuts at AAO offering real-world data access, point-of-care site-finding, and a hybrid AI and human reading center for clinical trials.
Academy Optometry 2026 kicks off in Anaheim
Events

Academy Optometry 2026 kicks off in Anaheim

American Academy of Optometry’s annual meeting opens on the West Coast with new formatting and a look ahead to 2027.
Legato startup debuts with AI-powered hearing glasses
Business

Legato startup debuts with AI-powered hearing glasses

Company emerges from stealth with $12 million in financing and a sneak peek of the Legato Frames, designed with patented hearing-assistance tech.
Rosacea may double risk for DR progression
Research

Rosacea may double risk for DR progression

Patients with rosacea and early-stage DR had more than twice the risk of progressing to proliferative disease—and a higher need for retinal intervention over 5 years.
OCuSOFT launches Retaine Ultra PF in a multi-dose bottle
Products

OCuSOFT launches Retaine Ultra PF in a multi-dose bottle

Marketed as a daily, multi-dose lubricant eye drop, this new addition offers fact-acting hydration and a “moisture-rich” formulation for sensitive eyes.
Eyes On Eyecare and the Intrepid Eye Society launch new video channel
Events

Eyes On Eyecare and the Intrepid Eye Society launch new video channel

Inside Intrepid offers dynamic discussions and a rare, behind-the-scenes look at how top ODs approach and manage complex topics in clinical practice.
Study: Pickleball-related eye injuries on the rise
Research

Study: Pickleball-related eye injuries on the rise

National review finds rising emergency visits, frequent ball-strike trauma, and a clear case for protective eyewear.
Eyedaptic launches latest version of AI-based smart glasses for AMD
Products

Eyedaptic launches latest version of AI-based smart glasses for AMD

Designed for patients with retinal diseases, the EYE7 is an integrated wearable solution with real-time vision enhancements and a new visual assistant.
FDA approves FDC Limited's pilocarpine HCl ophthalmic solution
Products

FDA approves FDC Limited's pilocarpine HCl ophthalmic solution

ANDA approval for generic eye drop extends to three concentrations: 1%, 2%, and 4%.
Ollin Biosciences debuts with next-gen ophthalmic pipeline
Business

Ollin Biosciences debuts with next-gen ophthalmic pipeline

Biotech launches with $100 million financing and a lead program addressing wet AMD and DME via a higher potency VEGF/Ang2 bispecific antibody.
Pivotal study showcases enVista Envy IOL's full range of vision
Research

Pivotal study showcases enVista Envy IOL's full range of vision

Data includes meeting all efficacy and safety outcomes, with the lens demonstrating statistical superiority in visual outcomes and a favorable dysphotopsia profile.
Scope introduces OPTASE HYLO FORTE dry eye drops
Products

Scope introduces OPTASE HYLO FORTE dry eye drops

Artificial tear is formulated with active glycerin for moderate-to-severe dry eye disease, offering extra moisture and a protective cushion for long-lasting relief.
FDA extends review period for EYLEA HD expanded labeling
Pipeline

FDA extends review period for EYLEA HD expanded labeling

Delay follows a recent site inspection; proposed expansion includes a new indication, updated dosings for current indications, and a pre-filled syringe version.
4DMT releases 60-week phase 2 analysis on DME gene therapy
Pipeline

4DMT releases 60-week phase 2 analysis on DME gene therapy

Reported at ASRS, data supports sustained vision gains and a 78% reduction in supplemental injections for 4D-150’s highest dose as company preps for phase 3 trial.